Liquidia Corp. (LQDA) rose 8% after a judge in a long-standing patent dispute with United Therapeutics (UTHR) criticized the company's lawyers in a legal filing. United Therapeutics ticked lower by 1.2%.
Plaintiff United Therapeutics (UTHR) "does not explain how changing about ten keystrokes in an 8,500-word original while representing the original is unchanged is anything other than deceptive and, as Defendant states in its reply brief, 'backdated.'" Judge Richard G. Andrews wrote in a filing on Tuesday.
The judge asks that United Therapeutics (UTHR) provide the identity of the lawyer who “altered” the original interrogatory response.
Liquidia (LQDA) has a short interest of 15%. United Therapeutics is set to report Q2 results on Aug. 5.
More on Liquidia, United Therapeutics
- Liquidia - Why I Still Can't Buy Into The Bull Thesis Despite Eye-Popping Gains
- United Therapeutics: Trifecta Of 2026 Tyvaso Franchise Filings Makes It A Compelling Buy
- United Therapeutics Vs. Regencell Bioscience: I Choose Profits Over Promises
- Seeking Alpha’s Quant Spotlight: Highest and lowest rated healthcare stocks ahead of Q2
- United Therapeutics buys Thymmune Therapeutics